UK-based AI and machine learning firm PinPoint has raised more than £1 million to develop a test designed to rule out cancer in the early stages and save millions for the NHS in unnecessary testing.

Life Technologies acquired Pinpoint Genomics and its early-stage non-small-cell lung cancer test. The test is designed to identify early-stage patients at high risk for progression to late-stage ...

A new genetic test to gauge the aggressiveness of prostate cancer may help men decide whether they need to treat their cancer right away or can safely monitor it You can save this article by ...

An inexpensive, fast accurate DNA test that reveals a person's risk of developing certain diseases is expected to become a reality, thanks to new technology. An inexpensive, fast, accurate DNA test ...

Researchers are developing a blood test that can tell not only whether someone has cancer, but in what organ the tumors are lurking. The test could mean more prompt, potentially life-saving treatment ...

CARLSBAD, Calif., July 25, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced the acquisition of Pinpoint Genomics, Inc., and its early-stage non-small cell lung cancer ...

Colon cancer is one of the top three deadliest forms of cancer - in part because it's often diagnosed so late. Now a groundbreaking study could pinpoint the disease easier, and earlier. The ...

To have surgery or not to have surgery? That is the big question for hundreds of thousands of Americans diagnosed each year with a pancreatic cyst. The dilemma? While cysts are very common, most will ...